News

thorax.bmj15d
SZ alpha-1 antitrypsin deficiency and pulmonary disease: more like MZ, not like ZZ - Thorax
The ZZ genotype of alpha-1 antitrypsin deficiency (AATD) is associated with COPD regardless of smoking. Heterozygous MZ-AATD is recognised as a moderate deficiency state, increasing the risk of COPD ...
The Daily News15d
Alpha-1 Antitrypsin Deficiency Market Research 2025-2035, Competitive Analysis of Grifols, CSL Behring, Takeda Pharmaceuticals, LFB Biotechnologies ... - The Daily News
Alpha-1 Antitrypsin Deficiency Market Research 2025-2035, Competitive Analysis of Grifols, CSL Behring, Takeda Pharmaceuticals, LFB Biotechnologies, GlaxoSmithKline, AstraZeneca, Merck, Pfizer - ...
Yahoo Finance18d
Alpha-1 Antitrypsin Deficiency Market Research 2025-2035: Rising Demand for AATD Treatments Fuels Expansion with North America Leading - Yahoo Finance
The global alpha-1 antitrypsin deficiency (AATD) market is expanding, driven by advances in diagnosis, treatment, and growing awareness. Key players like Grifols, CSL Behring, and Pfizer lead ...
Morningstar24d
2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC ...
Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the 1/1.5 mg/kg group (N=10), the confirmed ORR was 30.0% and the DCR was 90.0%, while that of the 3 mg ...
Morningstar29d
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - Morningstar
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) Provided by GlobeNewswire May 29, 2025, 8:01:00 PM ...